ZLAB
HEALTHCAREZai Lab Ltd
$21.01+0.03 (+0.14%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ZLAB Today?
No stock-specific AI insight has been generated for ZLAB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$15.96$44.34
$21.01
Fundamentals
Market Cap$2.4B
P/E Ratio—
EPS$-1.60
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-0.4%
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding112.4M
ZLAB News
20 articles- Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to SayYahoo Finance·May 7, 2026
- Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate UpdatesYahoo Finance·May 7, 2026
- Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday TradingYahoo Finance·Apr 30, 2026
- Asian Equities Traded in the US as American Depositary Receipts Flat in Wednesday TradingYahoo Finance·Apr 29, 2026
- Assessing Zai Lab (ZLAB) Valuation After Recent Share Price Momentum And Analyst Target ResetYahoo Finance·Apr 28, 2026
- Zai Lab Showcases 54% Brain Metastases Response for ZL-1310 ADC in SCLC at AACR Investor CallMarketbeat·Apr 26, 2026
- Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday TradingYahoo Finance·Apr 23, 2026
- Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026Yahoo Finance·Apr 22, 2026
- Zai Lab (ZLAB), Amgen (AMGN) Partner to Evaluate Combination Lung Cancer TherapyYahoo Finance·Apr 19, 2026
- Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic DiseasesYahoo Finance·Apr 18, 2026
- Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine CarcinomasYahoo Finance·Apr 17, 2026
- Asian Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday TradingYahoo Finance·Apr 15, 2026
- Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine CarcinomasGlobeNewswire Inc.·Apr 15, 2026
- Amgen And Zai Lab Trial Tests DLL3 Combo As Valuation Looks UndemandingYahoo Finance·Apr 14, 2026
- How Tavneos Safety Risks and New Oncology Pact Could Rebalance Amgen’s (AMGN) Risk‑Reward ProfileYahoo Finance·Apr 3, 2026
- Asian Equities Traded in the US as American Depositary Receipts Surge in Wednesday TradingYahoo Finance·Apr 1, 2026
- Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager TherapyYahoo Finance·Apr 1, 2026
- JPMorgan Cuts PT on Zai Lab Limited (ZLAB) to $32 From $39 – Here’s WhyYahoo Finance·Mar 31, 2026
- Asian Equities Traded in the US as American Depositary Receipts Decline in Friday TradingYahoo Finance·Mar 27, 2026
- A Look At Zai Lab (ZLAB) Valuation After A Sharp Pullback And Fair Value GapYahoo Finance·Mar 25, 2026
All 20 articles loaded
Price Data
Open$20.98
Previous Close$20.98
Day High$21.46
Day Low$20.37
52 Week High$44.34
52 Week Low$15.96
52-Week Range
$15.96$44.34
$21.01
Fundamentals
Market Cap$2.4B
P/E Ratio—
EPS$-1.60
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-0.4%
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding112.4M
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—